Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD

Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, provide insights on the differences between therapies that require continuous use versus those that can be intermittently used for atopic dermatitis (AD), explore the potential of combination therapy, and discuss optimal efficacy and duration of therapy regimens to maximize patient outcomes.

EP: 1.Tackling Key Concerns in Atopic Dermatitis + Biologic Use

EP: 2.Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape

EP: 3.Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment

EP: 4.Experts Discuss Long-Term Effects and Monitoring in AD Therapy

Now Viewing

EP: 5.Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD

EP: 6.The Patient Journey: Effectively Managing AD Itch Early On

EP: 7.Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies

EP: 8.Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care

1. When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?
2. How do treatment options differ in terms of administration schedule (continuous versus non-continuous), and how does the need for breakthrough topical steroids influence your decision on therapy options?
3. In the managed care space, what is the role of combination therapy in AD and what restrictions might be considered?
4. From a payer’s perspective, how do you take into account when a product does not need continuous use and still be efficacious, potentially allowing for time off therapy?

Related Videos

Related Content

Advertisement

October 22nd 2024

FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines

Julia Bonavitacola

Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

October 22nd 2024

The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret

Laura Joszt, MA

In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

October 21st 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Brooke McCormick

Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.

Published: October 18th 2024 | Updated: October 18th 2024

A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff

Laura Joszt, MA

The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.

Related Content

Advertisement

October 22nd 2024

FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines

Julia Bonavitacola

Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

October 22nd 2024

The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret

Laura Joszt, MA

In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

October 21st 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Brooke McCormick

Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.

Published: October 18th 2024 | Updated: October 18th 2024

A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff

Laura Joszt, MA

The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.